Antiplatelet effect of NQ12: A possible mechanism through the arachidonic acid cascade

Journal of Pharmacological Sciences

Volumn 105, Issue 2, 2007, Pages 193-200

  Jin, Yong Ri ^a   Han, Xiang Hua ^a   Lee, Jung Jin ^a   Lim, Yong ^a   Kim, Tack Joong ^a   Yoo, Hwan Soo ^a   Hong, Jin Tae ^a   Lee, Chong Kil ^a   Yun, Yeo Pyo ^a  

^a Chungbuk National University   (South Korea)

Author keywords

Antithrombotic agent; Platelet aggregation; Thromboxane A2

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 1,4 NAPHTHOQUINONE DERIVATIVE; 12 HYDROXYICOSATETRAENOIC ACID; 2 CHLORO 3 [4 (ETHYLCARBOXY)PHENYL]AMINO 1,4 NAPHTHOQUINONE; AACOCF 3; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; COLLAGEN; IMIDAZOLE; NQ 12; PHOSPHOLIPASE A2 INHIBITOR; PROSTAGLANDIN H2; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; THROMBOXANE SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARACHIDONIC ACID METABOLISM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; NONHUMAN; RABBIT; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 36148980006     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0071006     Document Type: Article

References (30)

1. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Annu Rev Biochem. 1986;55:69-102.
2. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group. Circulation. 1993;87:659-675.
3. Aspirin for primary prevention of cardiovascular disease (revisited). Med Lett Drugs Ther. 2006;48:53.
4. Aspirin for primary prevention of cardiovascular disease. Med Lett Drugs Ther. 2000;42:18.
5. 2 activation in rabbit platelets. Eur J Pharmacol. 1995;291:343-350.
6. 2 in thrombin-stimulated human platelets. Biochim Biophys Acta. 1987;920:205-214.
7. 2 in activated platelets. Thromb Res. 1998;92:19-26.
8. 3H]arachidonic acid and changes in cytosolic free calcium in fura-2-loaded human platelets stimulated by ionomycin and collagen. Biochem J. 1986;235:869-877.
9. 2 is involved in the antiapoptotic effect of FK506 and cyclosporin a on astrocytes exposed to simulated ischemia in vitro. J Pharmacol Sci. 2006;102:77-87.
10. 2 is increased in type IIA hypercholesterolemic subjects. Atherosclerosis. 1986;60:61-66.
11. Seki T, Ishimoto T, Sakurai T, Yasuda Y, Taniguchi K, Doi M, et al. Increased excretion of urinary 20-HETE in rats with cyclosporine-induced nephrotoxicity. J Pharmacol Sci. 2005;97:132-137.
12. Nakao J, Ooyama T, Chang WC, Murota S, Orimo H. Platelets stimulate aortic smooth muscle cell migration in vitro. Involvement of 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid. Atherosclerosis. 1982;43:143-150.
13. Nakao J, Ito H, Chang WC, Koshihara Y, Murota S. Aortic smooth muscle cell migration caused by platelet-derived growth factor is mediated by lipoxygenase product(s) of arachidonic acid. Biochem Biophys Res Commun. 1983;112:866-871.
14. Nyby MD, Sasaki M, Ideguchi Y, Wynne HE, Hori MT, Berger ME, et al. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation. J Pharmacol Exp Ther. 1996;278:503-509.
15. Chen X, Yang L, Oppenheim JJ, Howard MZ. Cellular pharmacology studies of shikonin derivatives. Phytother Res. 2002;16:199-209.
16. Yuk DY, Ryu CK, Hong JT, Chung KH, Kang WS, Kim Y, et al. Antithrombotic and antiplatelet activities of 2-chloro-3-[4-(ethylcarboxy)-phenyl]-amino-1,4- naphthoquinone (NQ12), a newly synthesized 1,4-naphthoquinone derivative. Biochem Pharmacol. 2000;60:1001-1008.
17. Jin YR, Han XH, Zhang YH, Lee JJ, Lim Y, Chung JH, et al. Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-gamma2 phosphorylation and cyclooxygenase-1 activity. Atherosclerosis. 2007;194:144-152.
18. Born GV, Cross MJ. The aggregation of blood platelets. J Physiol. 1963;168:178-195.
19. 2 in vitro and suppressive effect of toki-syakuyaku-san on increased aggregability in hypercholesterolemic rabbit ex vivo.] Yakugaku Zasshi. 1989;109:869-876. (text in Japanese with English abstract)
20. 2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets. Biochem Pharmacol. 1997;54:259-268.
21. Lockhart LK, Pampolina C, Nickolaychuk BR, McNicol A. Evidence for a role for phospholipase C, but not phospholipase A2, in platelet activation in response to low concentrations of collagen. Thromb Haemost. 2001;85:882-889.
22. Sasaki M, Miyosawa K, Ohkubo S, Nakahata N. Physiological significance of thromboxane A2 receptor dimerization. J Pharmacol Sci. 2006;100:263-270.
23. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in G alpha(q)-deficient mice. Nature. 1997;389:183-186.
24. Sachinidis A, Flesch M, Ko Y, Schror K, Bohm M, Dusing R, et al. Thromboxane A2 and vascular smooth muscle cell proliferation. Hypertension. 1995;26:771-780.
25. Rolin S, Petein M, Tchana-Sato V, Dogne JM, Benoit P, Lambermont B, et al. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis. J Pharmacol Exp Ther. 2003;306:59-65.
26. Miyamoto M, Yamada N, Ikezawa S, Ohno M, Otake A, Umemura K, et al. Effects of TRA-418, a novel TP-receptor antagonist, and IP-receptor agonist, on human platelet activation and aggregation. Br J Pharmacol. 2003;140:889-894.
27. Rolin S, Dogne JM, Michaux C, Delarge J, Masereel B. Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins Leukot Essent Fatty Acids. 2001;65:67-72.
28. Poole A, Gibbins JM, Turner M, van Vugt MJ, van de Winkel JG, Saito T, et al. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J. 1997;16:2333-2341.
29. Nieswandt B, Schulte V, Bergmeier W, Mokhtari-Nejad R, Rackebrandt K, Cazenave JP, et al. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med. 2001;193:459-469.
30. Ozeki Y, Nagamura Y, Ito H, Unemi F, Kimura Y, Igawa T, et al. An anti-platelet agent, OPC-29030, inhibits translocation of 12-lipoxygenase and 12-hydroxyeicosatetraenoic acid production in human platelets. Br J Pharmacol. 1999;128:1699-1704.